CureOne Recognized by Medicare as a Leader in Quality Data Collection and Reporting
QCDR Status Cements Organization’s Dedication to Upholding Clinical Standards
WASHINGTON, Jan. 15, 2018 – CureOne™, a nonprofit movement dedicated to standardizing next generation sequencing (NGS) and connecting it with matched clinical outcome data, has been named a Medicare Quality Clinical Data Registry (QCDR), making it the only registry of its kind to achieve this status. Additionally, CureOne has established six Effective Care metrics and five Outcome Measures for Medicare that help physicians meet quality improvement metrics, as associated with clinically relevant biomarker testing.
CureOne Announces Partnership with Washington University to Advance Cancer Research
Washington, D.C. and St. Louis, MO (November 7, 2017) – CureOne™ (formerly known as MED-C), an independent nonprofit movement dedicated to standardizing next generation sequencing (NGS) and sharing genomic data with matched clinical outcome data, has formed a key partnership with Washington University School of Medicine in St. Louis. CureOne will work with the institution’s clinical Next Generation Sequencing laboratory, Genomics and Pathology Services (GPS), to unlock precision medicine and achieve the goals of the N1 Registry™, a revolutionary open-access database that links next-generation sequencing data with information about treatments and clinical outcomes.
ASCO’s TAPUR Study Continues its Expansion of Sites, Participants, and Collaborators
Chicago June 3, 2017 – The American Society of Clinical Oncology’s (ASCO®) Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility.
CureOne™ Announces Foundation Medicine Participation in its N1 Registry
Washington D.C. June 3, 2017 – CureOne (formerly known as MED-C), a non-profit organization dedicated to advancing precision medicine, is proud to announce the participation of Foundation Medicine as a cornerstone laboratory in CureOne’s N1 Registry™
CureOne™ Announces Partnership with Guardant Health
Washington D.C. June 3, 2017 – CureOne (formerly known as MED-C), a non-profit organization dedicated to advancing precision medicine, is proud to announce the participation of Guardant Health, the leader in comprehensive liquid biopsy testing, as a cornerstone laboratory in CureOne’s N1 Registry™.
Molecular Evidence Development Consortium (MED-C) Announces Name Change To CureOne
Washington D.C. June 1, 2017 – The Molecular Evidence Development Consortium (MED-C), a non-profit organization seeking to advance precision medicine, announced today it is changing its corporate name to CureOne™. The name change reflects the company’s unwavering commitment to patients.